Table 1 Demographics, ankylosing spondylitis (AS)-related inflammatory diseases, and pharmacological treatment in cases and controls
Demographics | Cases (n = 2453) | Controls (n = 10,257) |
|---|---|---|
Men, n (%) | 1569 (64) | 6587 (64) |
Year of birth, median (min–max) | 1971 (1964–1992) | 1971 (1964–1992) |
Age at first SpA-diagnosis (years), mean, SD (min–max) | 30, 6.2 (17–46) | 30, 6.2 (17–46) |
AS-related inflammatory diseasesa | ||
Iridocyclitis, n (%) | 453 (19) | 45 (0) |
Inflammatory bowel disease, n (%) | 102 (4) | 37 (0) |
Psoriasis, n (%) | 122 (5) | 79 (1) |
Pharmacological treatment in 2011b | ||
NSAID, n (%) | 1279 (52) | 9 (0) |
TNF inhibitor, n (%) | 553 (23) | NAc |
Methotrexate, n (%) | 169 (7) | 0 |
Sulphasalazine, n (%) | 263 (11) | 1 (0) |